Adagene (ADAG) announced a clinical trial collaboration with Roche (RHHBY) to evaluate the triple combination of Adagene’s ADG126 with Roche’s atezolizumab and bevacizumab in first-line treatment of advanced hepatocellular carcinoma. The collaboration will utilize Roche’s MORPHEUS-LIVER platform for rapid and efficient combination development. Under the collaboration, Roche will sponsor and conduct a randomized phase 1b/2 multi-national trial to evaluate the efficacy, safety and pharmacokinetics of ADG126 in combination with bevacizumab and atezolizumab, versus atezolizumab and bevacizumab alone, initially in 60 patients. Each company is supplying its respective anti-cancer agent(s) to support the trial. Adagene will retain global development and commercialization rights to ADG126. Additional financial details of the collaboration were not disclosed.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on ADAG:
- Adagene Announces Clinical Trial Collaboration to Evaluate Anti-CTLA-4 SAFEbody® ADG126 in Combination with Roche’s Standard-of-Care for First-Line Advanced Liver Cancer
- Adagene initiated with a Buy at H.C. Wainwright
- Adagene Announces Clinical Data at SITC 2022 on Anti-CTLA-4 NEObody™, ADG116, Showing Differentiated Safety and Anti-tumor Activity in Heavily Pre-treated Patients with Difficult-to-Treat Tumors
